Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

@article{Joensuu2006AdjuvantDO,
  title={Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.},
  author={Heikki Joensuu and Pirkko-Liisa Kellokumpu-Lehtinen and Petri Bono and Tuomo Alanko and Vesa V. Kataja and Raija Asola and Tapio Utriainen and Riitta Kokko and Akseli Hemminki and Maija Tarkkanen and Taina Turpeenniemi‐Hujanen and Sirkku Jyrkki{\"o} and Martti Flander and Leena Helle and Seija Ingalsuo and Kaisu Johansson and A-S. J{\"a}{\"a}skel{\"a}inen and Marjo Pajunen and Mervi Rauhala and Jaana Kaleva-Kerola and Tapio Salminen and Mika Leinonen and Inkeri Elomaa and Jorma Isola},
  journal={The New England journal of medicine},
  year={2006},
  volume={354 8},
  pages={
          809-20
        }
}
BACKGROUND We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment. METHODS We randomly assigned 1010 women with axillary-node-positive or high-risk node-negative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide. The 232… 

Figures and Tables from this paper

Adjuvant trastuzumab in HER2-positive breast cancer.
TLDR
The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer and the risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia.
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
TLDR
Docetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control in patients with previously untreated HER2-positive advanced breast cancer, which deserves further investigation in prospective trials.
Adjuvant trastuzumab therapy for HER2-positive breast cancer.
TLDR
The addition of trastuzumab to adjuvant chemotherapy provides significant survival benefits with a positive benefit/risk ratio, and ongoing and planned trials correlated with basic science will enhance the understanding of HER2-positive disease, leading to treatment optimization and further improvements in patient outcomes.
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
TLDR
Adjuvant trastuzumab therapy reduces the risk of relapse similarly across subgroups defined by nodal status and steroid hormone receptor status, even those at relatively low risk for relapse.
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡
TLDR
This study failed to show the non-inferiority of a shorter trastuzumab administration, but a 9-week administration decreases the risk of severe cardiac toxicity and can be an option for patients with cardiac events during treatment and for those with a low risk of relapse.
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
TLDR
Sequential administration of preoperative doxorubicin and cyclophosphamide followed by a taxane and trastuzumab combination is safe in women with primary operable HER2+ breast cancer and is associated with a high pCR rate.
Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
TLDR
The trastuzumab adjuvant trial 006 shows for the first time that a nonanthracycline-containing regimen with trastzumab has equivalent efficacy in decreasing the recurrence of breast cancer, with less incidence of cardiotoxicity when compared to anthracy Clines-containing trastazumabAdjuvant regimens.
Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
TLDR
Compared with 1 year, shorter duration of adjuvant trastuzumab is associated with statistically significantly worse DFS and OS despite favorable cardiotoxicity profile.
Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
TLDR
Non-anthracycline chemotherapy with dual anti-HER2 targeting of trastuzumab and pertuzumAB represents one of the preferred neoadjuvant regimens to achieve higher pathologic complete response (pCR) rates and better clinical outcomes.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
TLDR
One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
TLDR
The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
TLDR
Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
  • M. Marty, F. Cognetti, J. Extra
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
Tastuzumab combined with docetaxel is superior to docetAXel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
Trastuzumab-based combinations in metastatic breast cancer: how to make a choice.
TLDR
Data is summarized on trastuzumab-based combinations with particular attention to the risk benefit ratio of these therapies and HER2 testing by immunohistochemistry or fluorescence in situ hybridization.
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
TLDR
Treatment with adjuvant FEC 100 demonstrated superior DFS and OS versus FEC 50 at 10 years of follow-up, and was not offset by long-term complications such as cardiac toxicity and second malignancy.
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
TLDR
Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials.
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
TLDR
The synergistic interaction of rhuMAb HER2 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive interaction with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cancer cells demonstrates that these are rational combinations to test in human clinical trials.
...
...